SRR2932835
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.220
- OXIDATIVE_PHOSPHORYLATION+0.200
- MYC_TARGETS_V2+0.180
- CHOLESTEROL_HOMEOSTASIS+0.160
- KRAS_SIGNALING_DN+0.160
- PEROXISOME+0.150
- E2F_TARGETS+0.130
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.130
- UV_RESPONSE_UP+0.090
- ESTROGEN_RESPONSE_LATE+0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.580
- TGF_BETA_SIGNALING-0.490
- PROTEIN_SECRETION-0.470
- UV_RESPONSE_DN-0.450
- ANGIOGENESIS-0.430
- HEDGEHOG_SIGNALING-0.380
- HYPOXIA-0.380
- WNT_BETA_CATENIN_SIGNALING-0.340
- INTERFERON_ALPHA_RESPONSE-0.320
- MITOTIC_SPINDLE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A54Y-01A-11R-A466-07 | — | B | 0.860 |
| 2 | TCGA-P3-A6SW-01A-11R-A34R-07 | — | — | 0.797 |
| 3 | TCGA-P3-A5Q5-01A-11R-A28V-07 | — | — | 0.795 |
| 4 | TCGA-CV-A45W-01A-11R-A24Z-07 | — | — | 0.788 |
| 5 | TCGA-53-A4EZ-01A-12R-A24X-07 | — | cohortA3 | 0.778 |
| 6 | TCGA-60-2726-01A-01R-0851-07 | — | cohortSQ1 | 0.777 |
| 7 | SRR2016945 | — | — | 0.777 |
| 8 | TCGA-KU-A6H7-06A-21R-A31N-07 | — | — | 0.777 |
| 9 | TCGA-E2-A576-01A-11R-A31O-07 | — | B | 0.769 |
| 10 | ERR2278846 | — | — | 0.758 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |